US Edition
News from urologytimes.com
We’ve assigned a media bias rating of unknown to urologytimes.com. You can read more about our methodology here.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top urologytimes.com News
Health · United StatesU.S. health officials have expanded approval of a much-debated drug aimed at boosting female libido, saying the once-a-day pill can now be taken by postmenopausal women up to 65 years old.See the Story
FDA OKs libido-boosting pill for older women who have gone through menopause
67% Center coverage: 78 sources
United States · United StatesFDA clears expanded use of AKEEGA as the first PARP-based precision combo for BRCA2-mutated mCSPC, cutting progression or death 54 percent and delaying symptoms 59 percent in Phase 3.See the Story
Johnson & Johnson (NYSE: JNJ) Gets FDA OK; AKEEGA Delays BRCA2 mCSPC Progress 59 Percent
61% Center coverage: 36 sources
